Anavex Life Sciences Corp. (AVXL.OB) Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
3/10/2014 9:50:19 AM
NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research report published in the current issue of peer-reviewed scientific journal Neuroscience Letters. The Company is encouraged by the report because its results point to potential for ANAVEX 2-73 to treat ALS, also known as Lou Gehrig's disease. Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models.
Help employers find you! Check out all the jobs and post your resume.
comments powered by